#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ewing's sarcoma recurrent Osteosarcoma metastatic Antiphospholipid antibodies Neuropathy peripheral Solitary fibrous tumour Cardiac failure acute Glycogen storage disease type V Andersen-Tawil syndrome Isodicentric chromosome 15 syndrome Macular telangiectasia Metastatic malignant melanoma Short-bowel syndrome Turner's syndrome Nephroblastoma Bulbospinal muscular atrophy congenital More trials…

    Learn about Rare Diseases

    Retinitis pigmentosa – Trials in Disease Malignant fibrous histiocytoma – Diagnostics Bronchopulmonary dysplasia – Diagnostics Langerhans cell sarcoma – Basic Information Piriformis syndrome – Diagnostics Antithrombin III deficiency – Life with Disease Malignant fibrous histiocytoma – Life with Disease Gaucher’s disease type III – Life with Disease Osteosarcoma Combined immunodeficiency – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gfh925 Nortriptyline Hydrochloride Dorzolamide Hydrochloride Tinengotinib Hmb-001 Perflubutane Dabrafenib Mesylate Degarelix 20-HYDROXYECDYSONE Ag13909 Telitacicept L-ALANINE Ly3298176 VANADIUM OXIDE SULFATE Oleclumab 6QC-ICG Camonsertib Azd3470 Setrusumab Xanomeline Tartrate More therapies…

    Learn about Your Condition

    Menopausal symptoms Neuromuscular scoliosis Krabbe's disease Pulmonary vascular disorder Immunodeficiency Genital infection female Acute promyelocytic leukaemia Diabetes insipidus Renal impairment Dementia Injury Papillary thyroid cancer Procedural hypotension Myeloproliferative neoplasm Bladder cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Alport’s syndrome

  • Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dapagliflozin
    • Placebo
    Germany

  • Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glomerulonephritis minimal lesion
    • Alport’s syndrome
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • Sparsentan
    Germany Italy The Netherlands Poland Spain Sweden

  • A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

    Not recruiting

    2 1
    Czechia France Germany Italy Poland Portugal +1

  • Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Alport’s syndrome
    Investigated Drugs:
    • Vonafexor
    France Germany Spain

  • Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Alport’s syndrome
    • Focal segmental glomerulosclerosis
    Investigated Drugs:
    • R3R01
    Belgium France Germany The Netherlands

  • Study on the Safety and Effects of Setanaxib for Patients with Alport Syndrome

    Not recruiting

    2 1
    Investigated Diseases:
    • Alport’s syndrome
    Investigated Drugs:
    • Setanaxib
    Austria Czechia France Lithuania Slovakia Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!